Oncolytics Biotech announced the presentation of their REO 033 trial-in-progress at the ESMO Congress 2026, evaluating pelareorep combined with FOLFIRI and bevacizumab for second-line treatment of RAS-mutant, microsatellite-stable metastatic colorectal cancer. This randomized study aims to confirm promising results from a previous trial (REO 022) that showed pelareorep doubled progression-free survival compared to standard care. The trial's primary endpoint is objective response rate, with secondary endpoints including overall survival and safety. Positive FDA interactions may lead to an expanded pivotal study and potential accelerated approval, highlighting pelareorep's potential to improve treatment options in a challenging market segment.
Oncolytics Biotech's REO 033 trial progress in colorectal cancer offers context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 20, 2026 19:43 WIB: out of 150 priced US health-sector stocks, 89 rose and 58 fell. Notable movers include CTXR at USD 0.45 with a +5.19% change and a typical hold time of 18 days, ENVB at USD 1.34 down -4.96% with 100% sell order activity, and MMED at USD 17.17 down -3.49% with an 11-day hold time.
SpaceX is set to report its Q3 2026 earnings with analysts expecting adjusted EPS of $0.13-$0.14 and revenue around $12.8 billion, a 64% increase year-over-year. Investors will closely watch Starlink's cash flow and the expanding AI infrastructure se...
RoyaLand Company Ltd. announced Palazzo Chronicles, a free-to-play mobile match-3 puzzle game set in 19th-century Piedmont during Italy's reunification. Players help Adelaide restore her inherited family castle by solving puzzles and rebuilding rooms...
Route 92 Medical has secured a $100 million senior secured debt facility from Trinity Capital to strengthen its balance sheet and support ongoing product innovation and commercial growth. The funding will help the company expand its neurovascular int...
American Electric Power (AEP) has a $147 price target from BTIG, implying a 17.9% upside from its current $124.72 price. The company is advancing a 960-megawatt nuclear project in Indiana with funding and power purchase support from Amazon, and a $4 ...
RBB Bancorp reported Q3 2026 earnings of $0.74 per share, surpassing the $0.58 estimate, and revenue of $36.87 million, a 13.2% increase year-over-year that beat forecasts. The bank improved key metrics including net interest margin rising to 3.16% a...
